Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Abstract: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). Standard treatment involves immunosuppressive therapy (IST), which carries a significant risk of serious infections, the leading cause of death in patien...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Inga M. Schimansky, Christiane Dobbelstein, Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul Knöbl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Möhnle, Katharina Holstein, Hermann Eichler, Sonja Werwitzke, Andreas Tiede
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2025-11-01
Serier:	Blood Advances
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2473952925004847
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!